Lapatinib plus capecitabine for HER2-positive advanced breast cancer

Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark Berger, Cristina Oliva, Stephen D Rubin, Steven Stein, David Cameron

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients. METHODS: Women with HER2-positive, locally advanced or metastatic breast cancer that had progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab were randomly assigned to receive either combination therapy (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter of body-surface area on days 1 through 14 of a 21-day cycle) or monotherapy (capecitabine alone at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle). The primary end point was time to progression, based on an evaluation by independent reviewers under blinded conditions. RESULTS: The interim analysis of time to progression met specified criteria for early reporting on the basis of superiority in the combination-therapy group. The hazard ratio for the independently assessed time to progression was 0.49 (95% confidence interval, 0.34 to 0.71; P
Original languageEnglish
Pages (from-to)2733-2743
Number of pages11
JournalNew England Journal of Medicine
Volume355
Issue number26
DOIs
Publication statusPublished - 28 Dec 2006

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Deoxycytidine
  • Disease Progression
  • Female
  • Fluorouracil
  • Heart Diseases
  • Humans
  • Middle Aged
  • Proportional Hazards Models
  • Protein Kinase Inhibitors
  • Quinazolines
  • Receptor, erbB-2
  • Survival Analysis

Fingerprint

Dive into the research topics of 'Lapatinib plus capecitabine for HER2-positive advanced breast cancer'. Together they form a unique fingerprint.

Cite this